Monday, 25 Mar 2019

You are here

Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis

A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).

Using claims data from Medicare and MarketScan, researchers from Harvard assessed the frequency of cardiovascular (CV) outcomes in RA patients receiving either ABA or TNFi.  The primary outcome was a composite cardiovascular end point of myocardial infarction (MI), stroke/transient ischemic attack, and coronary revascularization.

The study included 13 039 PS‐matched patients on either abatacept (ABA) or TNFi.  Background diabetes (DM) was found 34.7% of Medicare and 19.8% of MarketScan patients.

CV events were less frequent with abatacept use versus TNF inhibitor; the HR was 0.81 (0.66–0.99) in Medicare and 0.95 (0.74–1.23) in MarketScan, with a pooled HR of 0.86 (95% CI, 0.73–1.01; P=0.3 for heterogeneity).

While those with diabetes had an even lower CV event rate for ABA vs. TNFi (HR 0.74; 95%CI 0.57–0.96; P=0.7) for heterogeneity), the same was not seen in those without diabetes  (pooled HR 0.94; 95% CI, 0.77–1.14; P=0.4).

In RA patients, ABA was be associated with a modest reduction in cardiovascular risk (compared with TNFi), particularly in patients with DM.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.